AQXP vs. LQDA, ETNB, SPRY, ARDX, EVO, OPK, OCUL, GPCR, CALT, and SNDX
Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Liquidia (LQDA), 89bio (ETNB), ARS Pharmaceuticals (SPRY), Ardelyx (ARDX), Evotec (EVO), OPKO Health (OPK), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "medical" sector.
Aquinox Pharmaceuticals vs.
Aquinox Pharmaceuticals (NASDAQ:AQXP) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Aquinox Pharmaceuticals received 93 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 68.67% of users gave Liquidia an outperform vote.
71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by insiders. Comparatively, 30.1% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aquinox Pharmaceuticals has a net margin of 0.00% compared to Liquidia's net margin of -765.38%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Liquidia's return on equity.
Liquidia has a consensus target price of $26.63, indicating a potential upside of 76.44%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals has higher revenue and earnings than Liquidia.
Aquinox Pharmaceuticals has a beta of -7.37, suggesting that its stock price is 837% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.
In the previous week, Liquidia had 20 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 20 mentions for Liquidia and 0 mentions for Aquinox Pharmaceuticals. Liquidia's average media sentiment score of 0.99 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.
Summary
Liquidia beats Aquinox Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Aquinox Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquinox Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AQXP) was last updated on 3/30/2025 by MarketBeat.com Staff
